Abstract:

Triple-positive breast cancer (TPBC) refers to breast cancer with positive expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2), accounting for 5%-10% of all pathological types of breast cancer. TPBC is a special subtype of Luminal B breast cancer, which can receive both endocrine therapy and targeted therapy. TPBC is a special subtype of Luminal B breast cancer, which can receive both endocrine therapy and targeted therapy. The current guidelines recommend that anti-HER2-targeted therapy combined with chemotherapy is the first choice for TPBC treatment. However, the pathological complete response rate of TPBC is lower than that of hormone receptor negative/HER2-positive breast cancer. Moreover, patients with estrogen receptor expression >30% benefit less from anti-HER2-targeted therapy combined with chemotherapy. With the advent of various anti-HER2 targeted drugs and the clinical application of cyclin-dependent kinase 4 and 6 inhibitors, the combination of targeted therapy and endocrine therapy becomes possible for highly selected patients. This article reviewed the research progress of TPBC endocrine therapy combined with targeted therapy.

Key words: Triple-positive breast cancer, Endocrine therapy, Targeted therapy